Crossmark

cMET inhibitor crizotinib impairs angiogenesis and reduces tumor burden in the C3(1)-Tag model of basal-like breast cancer

Published Online: 2016-03-19

Published Print: 2016-12

Authors

Cozzo, Alyssa J.

Sundaram, Sneha

Zattra, Ottavia

Qin, Yuanyuan

Freemerman, Alex J.

Essaid, Luma

Darr, David B.

Montgomery, Stephanie A.

McNaughton, Kirk K.

Ezzell, J. Ashley

Galanko, Joseph A.

Troester, Melissa A.

Makowski, Liza
Funding

Funding for this research was provided by:

National Cancer Institute (CA180134)

The Mary Kay Foundation

University of North Carolina at Chapel Hill (University Cancer Research Fund (UCRF), UCRF, Gold Summer Undergraduate Research Fellowship, UNC Honors Research Award, Royster Society of Fellows, Integrative Vascular Biology Fellowship)

National Institute of Diabetes and Digestive and Kidney Diseases (034987, 056350)

Sanofi
License Information

Text and Data Mining valid from 2016-03-19

Version of Record valid from 2016-03-19
More Information

Article History

Received: 9 February 2016

Accepted: 22 February 2016

First Online: 19 March 2016

Document is current